Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,131 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

NCT06125795

Conditions
Behavior, Chronic Disease, Chronic Lymphocytic Leukemia, +19 more
Locations
  • HUA - Txagorritxu /ID# 258263 Vitoria-Gasteiz, Alava, Spain
  • Sant Joan de Deu de Manresa /ID# 258266 Manresa, Barcelona, Spain
  • Hospital Universitari Mútua Terrassa /ID# 258267 Terrassa, Barcelona, Spain
  • Hospital Jerez De La Frontera /ID# 258282 Jerez de la Frontera, Cadiz, Spain
View all 25 locations
View Trial Details
Active, not recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +26 more
Locations
  • Local Institution - 0031 Anjo-shi, Aichi-ken, Japan
  • Local Institution - 0011 Nagoya, Aichi-ken, Japan
  • Local Institution - 0024 Toyohashi, Aichi-ken, Japan
  • Local Institution - 0017 Kamogawa, Chiba, Japan
View all 40 locations
View Trial Details
Active, not recruiting

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

NCT06752850

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Classic Hemophilia, +24 more
Locations
  • Sobi Investigational Site Milan, Italy
  • Sobi Investigational Site Naples, Italy
  • Sobi Investigational Site Rozzano, Italy
  • Sobi Investigational Site Oslo, Norway
View Trial Details
Active, not recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Michigan Ann Arbor, Michigan, United States
  • Washington University St Louis, Missouri, United States
  • Mount Sinai Medical Center New York, United States
  • MSKCC New York, United States
View all 34 locations
View Trial Details
Active, not recruiting

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

NCT04546620

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Colchester General Hospital Colchester, Essex, United Kingdom
  • East Kent Hospitals NHS Foundation Trust Canterbury, Kent, United Kingdom
  • Monklands Hospital Airdrie, United Kingdom
  • Victoria Hospital Blackpool, United Kingdom
View all 33 locations
View Trial Details
Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • LKH-Universtitätsklinikum Graz Graz, Austria
  • Landeskrankenhaus - Universitätskliniken Innsbruck Innsbruck, Austria
  • Medizinische Universität Wien Vienna, Austria
  • Hanusch Krankenhaus Vienna, Austria
View all 181 locations
View Trial Details

Related conditions